Abivax Upsizes Public Offering to $800M, Oversubscribed Amid Strong Demand
ABVX has more than doubled off its 52-week low of $7.41 on elevated volume (4.7× avg).
Summary
Abivax has priced its public offering of American Depositary Shares, raising $800 million. This offering was upsized from the initially announced $600 million and was oversubscribed, indicating strong investor demand. The capital infusion significantly extends the company's cash runway into Q2 2029, providing critical funding for the potential commercialization of its lead drug candidate, obefazimod, which recently delivered positive Phase 3 results. The offering is expected to close on July 6, 2026.
At the time of this announcement, ABVX was trading at $137.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $7.41 to $148.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.